By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ThromboGenics NV 

Gaston Geenslaan 1

Heverlee    B-3001  Belgium
Phone: 32-0-16-751310 Fax: 32-0-16-751311


Company News
ThromboGenics NV (TBGNF) Long-Time Non-Executive Director Thomas Clay Appointed Chairman Of The Board Of Directors 6/15/2017 11:16:29 AM
ThromboGenics NV (TBGNF) To Present The Industry Pipeline Of DME Treatments At Upcoming European Society Of Ophthalmology Congress, Barcelona, Spain 6/8/2017 10:49:35 AM
ThromboGenics NV (TBGNF) To Present THR-317 Pre-Clinical Research Findings At The European Association For The Study Of Diabetes, Eye Complications Study Group (EASDec) Meeting In Budapest, Hungary 5/24/2017 1:21:19 PM
ThromboGenics NV (TBGNF) Business Update - Q1 2017 5/12/2017 8:15:39 AM
New ThromboGenics NV (TBGNF) Ophthalmic Research Findings Presented At Association for Research in Vision & Ophthalmology 2017 Annual Vision Research Meeting In Baltimore 5/2/2017 10:32:07 AM
ThromboGenics NV (TBGNF) Achieves Important Milestone In The Development Of THR-149, A Novel Plasma Kallikrein Inhibitor For Diabetic Macular Edema 4/20/2017 10:37:29 AM
Bicycle Therapeutics Announces A Candidate Preclinical Milestone In Its Ophthalmology Alliance With ThromboGenics NV (TBGNF) 4/20/2017 6:28:46 AM
ThromboGenics NV (TBGNF) Business Update – FY 2016 3/16/2017 11:52:13 AM
ThromboGenics NV (TBGNF) Release: Pharma Enrolls First Patients In Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) For Diabetic Macular Edema (DME) 1/10/2017 9:56:50 AM
ThromboGenics NV (TBGNF) Announces Protocol Amendment To Phase II CIRCLE Trial Evaluating THR-409 (Ocriplasmin) In Patients With Non-Proliferative Diabetic Retinopathy (NPDR) 12/28/2016 9:12:06 AM